By Dr. Melanie Doyle-Eisele, Senior Director of Life Sciences & Head of Federal Business Development
Federal funding remains one of the most attractive opportunities for emerging and mid-sized life sciences companies. Grants and federal contracts offer the potential to accelerate research, validate innovation, and scale programs that might otherwise struggle to secure private investment. However, not all federal funding mechanisms operate the same way. The distinction between grants and contracts represents a fundamental shift in expectations, execution, and risk.
Organizations that fail to understand this shift often encounter challenges that extend beyond paperwork, affecting timelines, budgets, and even long-term eligibility for future funding.
Understanding the Structural Shift from Grants to Contracts
At a high level, federal grants and contracts serve different purposes. Grants are designed to support exploratory science, allowing researchers to follow the data, adjust hypotheses, and deliver findings at a high level, often with reporting concentrated toward the end of the funding period.
Contracts, by contrast, are built around execution. They require companies to deliver on predefined milestones, adhere to strict timelines, and respond to ongoing government direction throughout the life of the project.
This difference fundamentally changes how drug development programs must be managed. Under a contract, scientific flexibility is replaced by operational discipline. Monthly reporting becomes standard, and deliverables are no longer open to interpretation. Instead, they are tightly defined, reviewed, and often revised multiple times based on agency feedback.
This shift can be jarring for biotech companies accustomed to grant-based research. What once functioned as a largely autonomous scientific effort becomes a highly structured collaboration with the federal government, with continuous, rigorous oversight.
The Operational Burden Behind Larger Budgets
One of the primary reasons companies pursue federal contracts is the scale of funding. While grants may range in the hundreds of thousands of dollars, contracts can reach into the tens of millions.
However, this increase in funding comes with a proportional increase in complexity. The reality is that larger budgets introduce heavier administrative demands, more rigorous compliance requirements, and significantly greater scrutiny.
Contracts require a robust project management infrastructure, including comprehensive reporting, Gantt charts, clearly defined task schedules, and continuous documentation of meeting minutes, financial tracking, and progress reports.
Even routine activities become time-consuming. Monthly reports have to be reviewed by government stakeholders, often returned with comments, and must be revised accordingly. In some cases, these revisions can extend far beyond initial expectations, adding months to project timelines.
Financial management also becomes more restrictive. Expenses that might be considered routine in other settings, such as upgraded travel or large team meals, may be disallowed under federal contract guidelines. Missteps in this area can result in rejected reimbursements or compliance concerns that jeopardize the contract.
The underlying principle is straightforward. Increased funding brings increased accountability.
Where Biotech Companies Go Wrong
Despite the high stakes, many first-time contract awardees underestimate the level of rigor required, approaching a contract as if it were a grant. This often leads to gaps in project management, insufficient staffing, and unclear reporting structures.
Another frequent issue is ambiguity in the proposal phase. When biotech companies fail to clearly define deliverables, timelines, and revision limits at the outset of the contract, they leave room for interpretation. This can result in additional work that was never budgeted, including repeated report revisions or expanded scope requirements.
There are also risks tied to government oversight. Unlike standardized regulatory frameworks, oversight in federal contracts can vary by agency and even evolve during the course of a project. This lack of consistency creates operational challenges, particularly for organizations without prior contracting experience.
In extreme cases, misalignment between the biotech and the government can halt progress entirely. There have been instances where contracts remained active for extended periods without any scientific work being completed, simply because both parties could not agree on study parameters.
The Risk of Falling Short
Failure to meet contract expectations carries significant consequences. Biotechs may lose funding mid-project, receive negative performance evaluations, or become ineligible for future opportunities.
The reputational impact can be substantial. Federal agencies track performance closely while communicating real-time feedback within and between agencies. A poor track record can limit access to future contracts or partnerships.
There is also the risk of delayed payments. If deliverables are not completed to the agency’s satisfaction, final payments may be withheld, placing financial strain on the biotech company.
These risks highlight the importance of treating contracts as operational commitments rather than exploratory opportunities.
What Biotech Companies Should Consider Before Pursuing Federal Contracts
For organizations evaluating whether to pursue federal contracts, several key considerations consistently emerge:
- Define scope with precision
- Invest in project management infrastructure
- Plan for extensive reporting and revisions
- Build financial discipline early
- Staff for flexibility and scale
- Align scientific goals with government priorities
- Understand the risk of funding disruption
- Consider contract research services for experienced guidance
A High-Reward, High-Risk Path
Federal contracts offer undeniable advantages. They provide access to significant funding, enable large-scale studies, and create opportunities for long-term collaboration with government agencies.
At the same time, they introduce a level of complexity that should not be underestimated. The difference between grants and contracts is not simply a change in funding source. It is a shift in mindset, requiring organizations to operate with greater precision, discipline, and accountability.
For biotech companies willing to invest in the necessary infrastructure and planning, contracts can be a powerful growth engine. For those who are unprepared, they can quickly become a source of frustration and risk.
Understanding the difference is the first step toward success.